MA44227A - Anticorps pour il-17c - Google Patents

Anticorps pour il-17c

Info

Publication number
MA44227A
MA44227A MA044227A MA44227A MA44227A MA 44227 A MA44227 A MA 44227A MA 044227 A MA044227 A MA 044227A MA 44227 A MA44227 A MA 44227A MA 44227 A MA44227 A MA 44227A
Authority
MA
Morocco
Prior art keywords
antibodies
fragments
relates
antibody
psoriasis
Prior art date
Application number
MA044227A
Other languages
English (en)
Other versions
MA44227B1 (fr
Inventor
Jan Dominik Haas
Jürgen Klattig
Nick Ernest René Vandeghinste
Original Assignee
Galapagos Nv
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Morphosys Ag filed Critical Galapagos Nv
Publication of MA44227A publication Critical patent/MA44227A/fr
Publication of MA44227B1 publication Critical patent/MA44227B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps ou des fragments d'anticorps se liant à l'il-17c humaine. En particulier, l'invention concerne des anticorps ou des fragments d'anticorps qui présentent des propriétés bénéfiques combinées et sont donc utiles pour le traitement d'êtres humains présentant, par exemple, une dermatite atopique ou un psoriasis.
MA44227A 2016-02-19 2017-02-17 Anticorps pour il-17c MA44227B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16156582 2016-02-19
EP16156651 2016-02-22
PCT/EP2017/053592 WO2017140831A1 (fr) 2016-02-19 2017-02-17 Anticorps anti-il-17c

Publications (2)

Publication Number Publication Date
MA44227A true MA44227A (fr) 2018-12-26
MA44227B1 MA44227B1 (fr) 2021-06-30

Family

ID=58057136

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43088A MA43088B1 (fr) 2016-02-19 2017-02-17 Anticorps anti-il-17c
MA44227A MA44227B1 (fr) 2016-02-19 2017-02-17 Anticorps pour il-17c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA43088A MA43088B1 (fr) 2016-02-19 2017-02-17 Anticorps anti-il-17c

Country Status (33)

Country Link
US (5) US20190048071A1 (fr)
EP (1) EP3416983B1 (fr)
JP (2) JP6535139B2 (fr)
KR (1) KR102715157B1 (fr)
CN (1) CN108699143B (fr)
AU (1) AU2017219837B2 (fr)
BR (1) BR112018016798A2 (fr)
CA (1) CA3014842A1 (fr)
CL (1) CL2018002340A1 (fr)
CO (1) CO2018008724A2 (fr)
CU (1) CU20180087A7 (fr)
CY (1) CY1124296T1 (fr)
DK (1) DK3416983T3 (fr)
EA (1) EA037813B1 (fr)
EC (1) ECSP18070641A (fr)
ES (1) ES2877376T3 (fr)
HR (1) HRP20211059T1 (fr)
HU (1) HUE054755T2 (fr)
IL (1) IL260733B2 (fr)
LT (1) LT3416983T (fr)
MA (2) MA43088B1 (fr)
MD (1) MD3416983T2 (fr)
MX (1) MX2018009860A (fr)
PH (1) PH12018501739A1 (fr)
PL (1) PL3416983T3 (fr)
RS (1) RS62012B1 (fr)
SG (1) SG11201806161TA (fr)
SI (1) SI3416983T1 (fr)
SM (1) SMT202100361T1 (fr)
TN (1) TN2018000289A1 (fr)
TW (1) TW201734041A (fr)
WO (1) WO2017140831A1 (fr)
ZA (1) ZA201806249B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1257289A1 (zh) * 2015-10-05 2019-10-18 Morphosys Ag 治疗和/或预防特应性皮炎的il-17c拮抗剂
IL260733B2 (en) 2016-02-19 2024-03-01 Morphosys Ag Antibodies for il-17c
WO2019057982A1 (fr) 2017-09-25 2019-03-28 Morphosys Ag Traitement de la dermatite atopique
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
US20220411465A1 (en) * 2019-11-22 2022-12-29 Morphosys Ag Eluate collection during antibody chromatography
CA3162172A1 (fr) * 2019-11-22 2021-05-27 Morphosys Ag Procede pour augmenter le rendement d'anticorps pendant une chromatographie par echange d'ions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1998056915A2 (fr) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
JP3577586B2 (ja) * 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
AU781396B2 (en) 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
KR20070084330A (ko) 2004-10-18 2007-08-24 지모제넥틱스, 인코포레이티드 가용성 ｚｃｙｔｏｒ21, 항-ｚｃｙｔｏｒ21 항체 및 결합파트너 및 염증에서의 사용방법
CA2624763A1 (fr) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Antagonistes de il-17c et methodes d'utilisation desdits antagonistes
CA2666842A1 (fr) 2006-10-18 2008-04-24 Zymogenetics, Inc. Antagonistes de l'il-17c et leurs procedes d'utilisation
EP3214442A1 (fr) * 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Traitement de l'inflammation gastro-intestinale, du psoriasis, de l'asthme, et du psoriasis a
SG189950A1 (en) 2010-11-19 2013-06-28 Morphosys Ag A collection and methods for its use
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
HUE037087T2 (hu) * 2011-10-19 2018-08-28 Morphosys Ag IL17C antagonistái gyulladásos rendellenességek kezelésére
WO2013186236A1 (fr) 2012-06-12 2013-12-19 Orega Biotech Antagonistes d'isoformes d'il-17 et leurs utilisations
AU2015367684A1 (en) * 2014-12-15 2017-07-06 Galapagos Nv Antibodies for IL-17C
IL260733B2 (en) 2016-02-19 2024-03-01 Morphosys Ag Antibodies for il-17c

Also Published As

Publication number Publication date
CL2018002340A1 (es) 2018-11-23
SMT202100361T1 (it) 2021-07-12
PL3416983T3 (pl) 2021-10-25
ZA201806249B (en) 2020-02-26
IL260733A (fr) 2018-09-20
US10259869B2 (en) 2019-04-16
CU20180087A7 (es) 2019-03-04
US20190048071A1 (en) 2019-02-14
TW201734041A (zh) 2017-10-01
EA201891594A1 (ru) 2019-01-31
ES2877376T3 (es) 2021-11-16
CN108699143B (zh) 2021-11-09
IL260733B2 (en) 2024-03-01
MA43088A1 (fr) 2019-05-31
EP3416983B1 (fr) 2021-04-07
KR20180109977A (ko) 2018-10-08
US11987621B2 (en) 2024-05-21
MD3416983T2 (ro) 2021-08-31
BR112018016798A2 (en) 2018-12-26
CA3014842A1 (fr) 2017-08-24
US20200216529A1 (en) 2020-07-09
US20250074978A1 (en) 2025-03-06
SI3416983T1 (sl) 2021-08-31
TN2018000289A1 (en) 2020-01-16
AU2017219837B2 (en) 2023-08-17
MX2018009860A (es) 2019-03-28
IL260733B1 (en) 2023-11-01
EP3416983A1 (fr) 2018-12-26
LT3416983T (lt) 2021-07-12
CO2018008724A2 (es) 2018-08-31
US10633439B2 (en) 2020-04-28
CY1124296T1 (el) 2022-11-25
RS62012B1 (sr) 2021-07-30
US20180340024A1 (en) 2018-11-29
KR102715157B1 (ko) 2024-10-10
CN108699143A (zh) 2018-10-23
AU2017219837A1 (en) 2018-08-09
DK3416983T3 (en) 2021-06-21
HRP20211059T1 (hr) 2021-10-01
JP6916834B2 (ja) 2021-08-11
WO2017140831A1 (fr) 2017-08-24
MA44227B1 (fr) 2021-06-30
EA037813B1 (ru) 2021-05-24
HUE054755T2 (hu) 2021-09-28
JP6535139B2 (ja) 2019-06-26
PH12018501739A1 (en) 2019-06-10
US20190202906A1 (en) 2019-07-04
JP2019511910A (ja) 2019-05-09
MA43088B1 (fr) 2020-10-28
SG11201806161TA (en) 2018-08-30
JP2019162119A (ja) 2019-09-26
ECSP18070641A (es) 2018-10-31

Similar Documents

Publication Publication Date Title
MA44227A (fr) Anticorps pour il-17c
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
WO2019224716A8 (fr) Anticorps spécifiques de gucy2c et leurs utilisations
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
PH12018501778A1 (en) Antibodies to tigit
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
WO2022051591A3 (fr) Anticorps anti-nectine-4 et leurs utilisations
MX2020009277A (es) Anticuerpos anti-phf-tau y usos de estos.
MY197821A (en) Anti-il-22r antibodies
MX2022001604A (es) Anticuerpos anti bdca-2.
MA38161A1 (fr) Anticorps anti-bmp-6
EA201992688A1 (ru) Средства, пути применения и способы лечения
ZA202006216B (en) Antibodies targeting glycoprotein vi
NZ778810A (en) Antibodies targeting c5ar
MA43600B2 (fr) Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire
GEP20237484B (en) Antibody variants
PH12023550198A1 (en) Antibody molecules to april and uses thereof
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MX2024002584A (es) Tratamientos para la dermatitis atopica.
MX2023009434A (es) Anticuerpos contra cd112r y usos de los mismos.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MA39559A1 (fr) Anticorps anti récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs utilisations
EA202193086A1 (ru) Ингибиторы аутофагии на основе фениламинопиримидинамида и способы их применения